Search

Your search keyword '"Chudej, Juraj"' showing total 23 results
Start Over Author "Chudej, Juraj"
23 results on '"Chudej, Juraj"'

2. Kardiotoxická liečba v onkohematológii.

Author

Sokol, Juraj, Nehaj, František, Chudej, Juraj, Lisá, Lenka, Lineková, Ľudmila, Jusko, Richard, Kecskés, Ivan, and Plameňová, Ivana

Subjects
CARDIAC hypertrophy, BRUTON tyrosine kinase, CARDIOTOXICITY, ATRIAL fibrillation, CELLULAR signal transduction
Abstract

Copyright of Cardiology Letters is the property of Slovak Society of Cardiology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

3. Paroxysmal nocturnal hemoglobinuria: A rare case of recurrent episodes of icterus

Author

Hoferica Jakub, Nosakova Lenka, Uhrik Peter, Vazanova Diana, Scur Matus, Chudej Juraj, and Banovcin Peter

Subjects
General Biochemistry, Genetics and Molecular Biology, General Nursing
Abstract

In this work we describe a rare case of a patient with paroxysmal nocturnal hemoglobinuria (PNH) developed on the background of specific medical history of morbus Gilbert with chronically elevated bilirubin and recurrent attacks of macroscopic haematuria. We focus on a differential diagnosis of the disease, its obstacles, and treatment options.

Published
2022
Full Text
View/download PDF

6. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

Author

Pavlik, Tomas, Janousova, Eva, Mayer, Jiri, Indrak, Karel, Jarosova, Marie, Klamova, Hana, Zackova, Daniela, Voglova, Jaroslava, Faber, Edgar, Karas, Michal, Polakova, Katerina Machova, Racil, Zdenek, Demeckova, Eva, Demitrovicova, Ludmila, Tothova, Elena, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Kozak, Tomas, Muzik, Jan, and Dusek, Ladislav

Published
2013
Full Text
View/download PDF

7. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia

Author

Harvanová, Ľubica, primary, Štulajterová, Viera, additional, Guman, Tomáš, additional, Ladická, Miriam, additional, Hlebašková, Monika, additional, Chudej, Juraj, additional, Šimek, Miroslav, additional, Štecová, Natália, additional, Flochová, Emília, additional, Kubala, Ján, additional, Simančíková, Iveta, additional, Drgoňa, Ľuboš, additional, Vranovský, Andrej, additional, Wild, Alexander, additional, Mistrík, Martin, additional, and Bátorová, Angelika, additional

Published
2021
Full Text
View/download PDF

8. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry

Author

Faber, Edgar, Mužík, Jan, Koza, Vladimír, Demečková, Eva, Voglová, Jaroslava, Demitrovičová, Ĺudmila, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Kozák, Tomáš, Tóthová, Elena, Jarošová, Marie, Dušek, Ladislav, and Indrák, Karel

Published
2011
Full Text
View/download PDF

13. Porovnanie skórovacích systémov na stanovenie rizika krvácania a tromboembolizmu u pacientov s fibriláciou predsiení a hemoragický šok u pacienta na triple terapii.

Author

Nehaj, František, Sokol, Juraj, Kubašková, Marianna, Mokáň, Michal, Chudej, Juraj, Péč, Jozef Martin, Mokáň, Marián, Edin, F. R. C. P., Galajda, Peter, and Michalová, Renáta

Subjects
VENOUS thrombosis, HEART failure, HEART diseases, PULMONARY embolism, CORONARY disease, DEVELOPED countries, STROKE
Abstract

Copyright of Pediatrie pro Praxi is the property of SOLEN sro and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019

14. Treatment Outcomes in Patients Treated with Tyrosine Kinase Inhibitors in "Slovak Registry of Chronic Myeloid Leukemia" (CAMELIA SK)

Author

Sninska, Zuzana, primary, Mistrik, Martin, additional, Slezakova, Katarina, additional, Demitrovicova, Ludmila, additional, Mikuskova, Eva, additional, Markuljak, Imrich, additional, Chudej, Juraj, additional, Stecova, Natalia, additional, Tothova, Elena, additional, Kafkova, Adriana, additional, Palasthy, Stanislav, additional, Lesko-Andrascikova, Jana, additional, Necasova, Tereza, additional, and Koritakova, Eva, additional

Published
2016
Full Text
View/download PDF

17. Evaluation of 5‐year imatinib treatment of 458 patients with CP ‐ CML in routine clinical practice and prognostic impact of different BCR ‐ ABL cutoff levels

Author

Klamová, Hana, primary, Poláková, Kateřina Machová, additional, Mužík, Jan, additional, Ráčil, Zdeněk, additional, Žáčková, Daniela, additional, Steinerová, Kateřina, additional, Karas, Michal, additional, Faber, Edgar, additional, Demečková, Eva, additional, Michalovičová‐Sninská, Zuzana, additional, Voglová, Jaroslava, additional, Demitrovičová, Ľudmila, additional, Mikušková, Eva, additional, Tóthová, Elena, additional, Chudej, Juraj, additional, Markuljak, Imrich, additional, Cmunt, Eduard, additional, Moravcová, Jana, additional, Dvořáková, Dana, additional, Michalová, Kyra, additional, Jarošová, Marie, additional, Šťastná, Markéta Marková, additional, Cetkovský, Petr, additional, DuŠek, Ladislav, additional, Koza, Vladimír, additional, Trněný, Marek, additional, and Indrák, Karel, additional

Published
2013
Full Text
View/download PDF

21. The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Author

Klamova, Hana, primary, Zackova, Daniela, additional, Faber, Edgar, additional, Steinerova, Katerina, additional, Karas, Michal, additional, Demeckova, Eva, additional, Voglova, Jaroslava, additional, Demitrovicova, Ludmila, additional, Tothova, Elena, additional, Chudej, Juraj, additional, Markuljak, Imrich, additional, Kozak, Tomas, additional, Cmunt, Eduard, additional, Jarosova, Marie, additional, Machova-Polakova, Katerina, additional, Michalova, Kyra, additional, Dusek, Ladislav, additional, Muzik, Jan, additional, Mistrik, Martin, additional, Mayer, Jiri, additional, Trneny, Marek, additional, and Indrak, Karel, additional

Published
2010
Full Text
View/download PDF

22. Prothrombin gene 20210A mutation in Slovak population.

Author

Chudej J and Plameňová I

Subjects
Abortion, Spontaneous epidemiology, Adolescent, Adult, Case-Control Studies, Female, Humans, Male, Middle Aged, Polymorphism, Genetic, Pregnancy, Slovakia, Thrombosis epidemiology, Young Adult, Heterozygote, Mutation, Prothrombin genetics
Abstract

Introduction: Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE). PTM is present in 2 % Caucasian population. The main aim of this study was to identify the PTM in the patients with positive history of thrombotic events vs. control subjects., Materials and Methods: The assessment of PTM was performed by the PCR analysis of the chromosomal DNA, which was isolated from the peripheral blood leukocytes., Results: Of the 2 274 patients included, 157 (6.9 %) were carriers of the PTM. The mutation was present only in 2.6 % (n = 8) of the 303 controls. The following clinical manifestations of PTM were analysed. We observed 123 venous thrombotic events, 46 arterial thrombosis and 14 spontaneous abortions. In this article we analyse other possible risk factors for thromboembolic events in patients with carriage of PTM., Conclusions: To our knowledge, this is the largest epidemiological study of PTM in Central Europe. Employing statistical analysis, we found relatively high prevalence of the PTM in both, the patients with positive thrombosis history (6.9 %), as well as in the control group (2.6 %). The risk of thrombosis by carriage of PTM is independent of age and gender. Study has shown relatively frequent presence of double carriership of PTM and factor V Leiden mutation (FVL).

Published
2016

23. Transcription of genes of p53-dependent apoptosis in acute leukaemia.

Author

Racay P, Hatok J, Hudecek J, Chudej J, Jurecekova J, and Dobrota D

Subjects
Actins genetics, Actins metabolism, Glyceraldehyde-3-Phosphate Dehydrogenases genetics, Glyceraldehyde-3-Phosphate Dehydrogenases metabolism, HSP70 Heat-Shock Proteins genetics, HSP70 Heat-Shock Proteins metabolism, Humans, Leukemia, Myeloid, Acute blood, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute pathology, Leukocytes, Mononuclear metabolism, Myeloid Cell Leukemia Sequence 1 Protein, Polymorphism, Single-Stranded Conformational, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Protein p53 metabolism, bcl-2-Associated X Protein genetics, bcl-2-Associated X Protein metabolism, bcl-X Protein genetics, bcl-X Protein metabolism, Apoptosis, Leukemia, Myeloid, Acute genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Transcription, Genetic, Tumor Suppressor Protein p53 genetics
Abstract

Tumour suppressor protein p53 prevents cancer development through various mechanisms, including the induction of apoptosis. We demonstrated that acute leukaemia, myeloblastic (AML) and lymphoblastic (ALL), is associated with significantly elevated levels of p53 and Bax mRNA in leukaemic cells. Regarding ALL, significantly elevated levels of Bcl-xL mRNA may explain the relative resistance of ALL cells to p53-dependent apoptosis. Altered alternative processing of Bcl-x and myeloid cell leukaemia-1 (MCL1) primary transcripts were observed in the case of AML and AML and ALL, respectively. We assumed that increased glyceraldehyde-3-phosphate dehydrogenase (gapdh) transcription and decreased MCL1s mRNA were not fully responsible for the dysregulation of p53-dependent apoptosis in the case of AML. In addition, transcription of hsp70.1 and Bcl-2 producing anti-apoptotic proteins was not affected in acute leukaemia.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results